- Kronos Bio (KRON) has filed an updated preliminary prospectus for an IPO of ~10.3M common shares at $16-18 per share.
- Net proceeds should be ~$159.3M at the midpoint.
- Underwriters' overallotment will be an additional ~1.54M shares.
- Net proceeds will be used to fund clinical trials, for development of SYK and CDK9 programs and other product candidates, for working capital and for other general corporate purposes.
- Previously: Kronos Bio on deck for IPO (Sept. 21)
- https://seekingalpha.com/news/3619710-kronos-bio-sets-ipo-terms
Monday, October 5, 2020
Kronos Bio sets IPO terms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.